Gilead Sciences said Thursday that it has exercised an option to license four cancer drugs from Arcus Biosciences, including an immunotherapy that works against a closely followed anti-cancer target called TIGIT.
In exchange for licensing rights to the four cancer drugs, Gilead is paying Arcus $725 million. The two companies will co-develop the drugs, share costs, and if approved, split profits in the U.S., the companies said.
For Gilead, the Arcus deal represents another potentially lucrative but risky effort to grow its cancer business, which has struggled to gain traction apart from its bespoke CAR-T therapies.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
